Results 181 to 190 of about 207,197 (306)

Assessing Risk Thresholds in Controlled Human Infection Models (CHIM)

Bioethics, EarlyView.
ABSTRACT Controlled Human Infection Models (CHIMs) are a type of clinical trial involving deliberately exposing human volunteers to an infectious agent. Compared to studies of natural infection, CHIMs offers distinctive benefits, from the ability to study presymptomatic infection to a direct assessment of the efficacy of vaccines and therapeutics in a ...
Alexa Nord‐Bronzyk, Barnaby Young, Jerry Menikoff, Julian Savulescu, G. Owen Schaefer   +4 more
wiley   +1 more source

Influenza Vaccines: Current Status, Adjuvant Strategies, and Efficacy. [PDF]

Vaccines (Basel)
Mokalla VR, Gundarapu S, Kaushik RS, Rajput M, Tummala H.   +4 more
europepmc   +1 more source

Advancements in Inorganic Chiral Nanomaterials for Anti‐Tumor Immunotherapy

Cancer Science, EarlyView.
Schematic illustration of how inorganic chiral nanomaterials enhance immune activation to promote tumor cell elimination through targeted delivery, immunogenic cell death, and immune microenvironment modulation. ABSTRACT While the past decade has witnessed unprecedented technological advancements, cancer remains a major health threat, with conventional
Siyu Chen, Qian Tang, Xiqian Chen, Yinghao Liang, Jin Qiu, Yongmei Liao, Changqiang Li, Hongru Yu, Fang Xie, Zongjunlin Liu   +9 more
wiley   +1 more source

Safety and heterogeneity of mRNA-based seasonal Influenza vaccines: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Saudi Med
Albargy HA, Othman AA.
europepmc   +1 more source

Drivers of bat researchers’ intent to adopt field hygiene practices

Conservation Biology, EarlyView.
Abstract Infectious disease is a growing threat to wildlife, with zoonotic transmission most likely at the human–wildlife interface. One underappreciated activity at this interface is fieldwork with wild animals, but associated risks can be mitigated through field hygiene (FH) practices, such as using personal protective equipment and other appropriate
Joanna L. Coleman, Ewan A. Macdonald, Abigail L. Rutrough, Tanja M. Straka, Todd D. Little, Zachary Stickley, Tigga Kingston   +6 more
wiley   +1 more source

Cross-reactivity between antibodies induced by European swine influenza vaccines and Spanish swine influenza strains. [PDF]

Front Vet Sci
Encinas P, Nogales A, Nelson MI, García-Sastre A, Del Real G.   +4 more
europepmc   +1 more source

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, EarlyView.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

Comparative analysis of cellular immune responses to four seasonal inactivated influenza vaccines in younger and older adults. [PDF]

J Immunol
Silva-Moraes V, Reis LR, Ross TM.
europepmc   +1 more source

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

Diabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo, Bianca Aparecida Siqueira, Luiz Felipe Azevedo Marques, Lucas Silva Mello, Fernando Augusto Lima Marson   +4 more
wiley   +1 more source

Next-Generation Influenza Vaccines and the Pandemic Horizon: Challenges, Innovations, and the Road Ahead. [PDF]

Vaccines (Basel)
Taaffe J, Lambach P, Gsell P, Ghiga I, Goldin S.   +4 more
europepmc   +1 more source